3-Chloro-4-hydroxyphenylboronic Acid → 1-{6-(3-Chloro-4-hydroxyphenyl)-4-[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]quinolin-3-yl}-2-methylpropan-1-one
반응식
Br[C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]=[CH:7][C:6]([C:12](=[O:16])[CH:13]([CH3:15])[CH3:14])=[C:5]2[N:17]1[CH2:22][CH2:21][CH:20]([CH2:23][N:24]2[CH2:28][CH2:27][CH2:26][CH2:25]2)[CH2:19][CH2:18]1.[Cl:29][C:30]1[CH:31]=[C:32](B(O)O)[CH:33]=[CH:34][C:35]=1[OH:36]>>[Cl:29][C:30]1[CH:31]=[C:32]([C:2]2[CH:3]=[C:4]3[C:9](=[CH:10][CH:11]=2)[N:8]=[CH:7][C:6]([C:12](=[O:16])[CH:13]([CH3:15])[CH3:14])=[C:5]3[N:17]2[CH2:18][CH2:19][CH:20]([CH2:23][N:24]3[CH2:25][CH2:26][CH2:27][CH2:28]3)[CH2:21][CH2:22]2)[CH:33]=[CH:34][C:35]=1[OH:36]참가 물질
3
실험 절차
Following general procedure D, 1-{6-bromo-4-[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]quinolin-3-yl}-2-methylpropan-1-one (30 mg, 0.068 mmol) was reacted with 3-chloro-4-hydroxyphenylboronic acid (17 mg, 0.100 mmol) to afford the desired product (18.9 mg, 56%) as an off-white solid: 1H NMR (500 MHz, CD3OD) δ 8.75 (s, 1H), 8.28 (d, J=1.2 Hz, 1H), 8.06-7.99 (m, 2H), 7.70 (d, J=2.3 Hz, 1H), 7.54 (dd, J=8.4, 2.3 Hz, 1H), 7.06 (d, J=8.4 Hz, 1H), 3.54-3.41 (m, 3H), 3.23-3.11 (m, 6H), 3.03 (d, J=6.8 Hz, 2H), 2.11-1.93 (m, 7H), 1.74-1.62 (m, 2H), 1.26 (d, J=6.9 Hz, 6H); ESI MS m/z 492 [C29H34ClN3O2+H]+; HPLC>99% (AUC), tR=10.93 min.